Indisulam
- CAS No.
- 165668-41-7
- Chemical Name:
- Indisulam
- Synonyms
- D04522;E-7070;ER-35744;INDISULAM;IndisulaM (E7070);INDISULAM iMpurity;Indisulam【SML1225】;E7070;ER-35744;D04522;Indisulam >=98% (HPLC);Indisulam, 10 mM in DMSO
- CBNumber:
- CB11011305
- Molecular Formula:
- C14H12ClN3O4S2
- Molecular Weight:
- 385.85
- MDL Number:
- MFCD00945325
- MOL File:
- 165668-41-7.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Melting point | 242-243 °C (decomp)(Solv: ethanol (64-17-5); water (7732-18-5)) |
|---|---|
| Boiling point | 668.9±65.0 °C(Predicted) |
| Density | 1.663±0.06 g/cm3(Predicted) |
| storage temp. | -20°C |
| solubility | DMSO : 100 mg/mL (259.17 mM; Need ultrasonic) |
| form | powder |
| pka | 8.14±0.30(Predicted) |
| color | white to beige |
| InChI | InChI=1S/C14H12ClN3O4S2/c15-12-8-17-14-11(12)2-1-3-13(14)18-24(21,22)10-6-4-9(5-7-10)23(16,19)20/h1-8,17-18H,(H2,16,19,20) |
| InChIKey | SETFNECMODOHTO-UHFFFAOYSA-N |
| SMILES | C1(S(NC2C3=C(C=CC=2)C(Cl)=CN3)(=O)=O)=CC=C(S(N)(=O)=O)C=C1 |
| NCI Dictionary of Cancer Terms | E7070 |
| FDA UNII | WJ98J3NM90 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H315-H319 | |||||||||
| Precautionary statements | P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313 | |||||||||
| WGK Germany | WGK 3 | |||||||||
| Storage Class | 11 - Combustible Solids | |||||||||
| Hazard Classifications | Eye Irrit. 2 Skin Irrit. 2 |
|||||||||
| NFPA 704 |
|
Indisulam price More Price(48)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | SML1225 | Indisulam ≥98% (HPLC) | 165668-41-7 | 5MG | $161 | 2026-04-30 | Buy |
| Sigma-Aldrich | SML1225 | Indisulam ≥98% (HPLC) | 165668-41-7 | 25MG | $637 | 2026-04-30 | Buy |
| Cayman Chemical | 22759 | Indisulam ≥98% | 165668-41-7 | 1mg | $28 | 2026-04-30 | Buy |
| Cayman Chemical | 22759 | Indisulam ≥98% | 165668-41-7 | 5mg | $70 | 2026-04-30 | Buy |
| Cayman Chemical | 22759 | Indisulam ≥98% | 165668-41-7 | 10mg | $125 | 2026-04-30 | Buy |
Indisulam Chemical Properties, Uses, Production
Uses
Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15[1][2].
Definition
ChEBI: Indisulam is a chloroindole that is 3-chloro-1H-indole substituted by a [(4-sulfamoylphenyl)sulfonyl]nitrilo group at position 7. It is a carbonic anhydrase inhibitor and a potential anti-cancer agent currently in clinical development. It has a role as an EC 4.2.1.1 (carbonic anhydrase) inhibitor and an antineoplastic agent. It is a chloroindole, a sulfonamide and an organochlorine compound.
Biochem/physiol Actions
Indisulam is a carbonic anhydrase inibitor and Antitumor CDK inhibitor. Indisulam targets the G1 phase of the cell cycle by depleting cyclin E. inducing p53 and p21, and inhibiting CDK2, causing a blockade in the G1/S transition.
in vivo
Indisulam (E7070, 12.5, 25, 50 (100) mg/kg) shows an antitumour spectrum in human cancer models[1].
| Animal Model: | Female BALB/c nu/nu mice aged 7 weeks (HCT116 colon, LX-1 lung, SW620 colon, HCT115 colon, PC-9 lung, DLD-1 colon and WiDr colon models)[1]. |
| Dosage: | 12.5, 25, 50 (100) mg/kg. |
| Administration: | IV daily for 4 days. |
| Result: | Exhibited anti-tumor activity. |
storage
Store at -20°C
References
[1] Ozawa Y, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur J Cancer. 2001 Nov;37(17):2275-82. DOI:10.1016/s0959-8049(01)00275-1
[2] Abbate F, et al. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23. DOI:10.1016/j.bmcl.2003.09.062
Indisulam Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| InvivoChem | 13549236410 | sales@invivochem.cn | China | 6745 | 58 |
| Shanghai Boyle Chemical Co., Ltd. | sales@boylechem.com | China | 2915 | 55 | |
| AdooQ BioScience, LLC | +1 (866) 930-6790 | info@adooq.com | United States | 2774 | 58 |
| ShangHai Caerulum Pharma Discovery Co., Ltd. | 18149758185 18149758185 | sales-cpd@caerulumpharma.com | China | 3493 | 58 |
| Bide Pharmatech Ltd. | 400-164-7117 18317119277 | product02@bidepharm.com | China | 40000 | 60 |
| AdooQ Bioscience CHINA | 025-58849295 | info@adooq.cn | China | 2981 | 60 |
| Credit Asia Chemical Co., Ltd. | +86 (21) 61124340 | China | 9739 | 58 | |
| LETOPHARM LIMITED | +86-21-5821 5861 | sales@letopharm.com | China | 2374 | 58 |
| Sigma-Aldrich | 021-61415566 800-8193336 | orderCN@merckgroup.com | China | 51389 | 80 |
| AN PharmaTech Co Ltd | 86(21)68097365 | sales@anpharma.net | China | 4875 | 55 |
| Supplier | Advantage |
|---|---|
| InvivoChem | 58 |
| Shanghai Boyle Chemical Co., Ltd. | 55 |
| AdooQ BioScience, LLC | 58 |
| ShangHai Caerulum Pharma Discovery Co., Ltd. | 58 |
| Bide Pharmatech Ltd. | 60 |
| AdooQ Bioscience CHINA | 60 |
| Credit Asia Chemical Co., Ltd. | 58 |
| LETOPHARM LIMITED | 58 |
| Sigma-Aldrich | 80 |
| AN PharmaTech Co Ltd | 55 |
View Latest Price from Indisulam manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Indisulam
165668-41-7
|
$30.00-61.00 | 99.62% | 10g | TargetMol Chemicals Inc. | ||
 |
2025-04-04 | Indisulam
165668-41-7
|
1KG | 98% | 1Ton | Henan Aochuang Chemical Co.,Ltd. | ||
 |
2020-01-14 | Indisulam
165668-41-7
|
$1.00 | 1g | 99% | 200kg | Career Henan Chemical Co |
